Medicine: FILSPARI (sparsentan)

Filspari (sparsentan) is an endothelin and angiotensin II receptor antagonist indicated to slow kidney function decline in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progression.

Filspari U.S. Prescribing Information Including Boxed Warning ›

About IgA nephropathy

IgA nephropathy (IgAN), also called Berger’s disease, is a rare progressive kidney disease characterized by the buildup of immunoglobulin A (IgA), a protein that helps the body fight infections, in the kidneys.

Learn More

Medicine: FILSPARI (sparsentan)

FILSPARI is an endothelin and angiotensin II receptor antagonist indicated to reduce proteinuria in adult and pediatric patients aged 8 years and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome

Filspari U.S. Prescribing Information Including Boxed Warning ›

About focal segmental glomerulosclerosis

Focal segmental glomerulosclerosis (FSGS) is a rare proteinuric kidney disorder in both children and adults that is defined by progressive scarring of the kidney and that often leads to kidney failure.

Learn More

Medicine: THIOLA EC, THIOLA (tiopronin)

THIOLA EC | THIOLA (tiopronin) is a reducing and complexing thiol indicated, in combination with high fluid intake, alkali, and diet modification, for the prevention of cystine stone formation in adults and pediatric patients 20 kg and greater with severe homozygous cystinuria, who are not responsive to these measures alone.

Thiola EC Prescribing Information ›

Thiola Prescribing Information ›

About cystinuria

Cystinuria is a rare genetic disorder that causes a buildup of an amino acid called cystine in the urine. This can result in the formation of cystine kidney stones.

Learn More

Investigational medicine: pegtibatinase

Pegtibatinase is a novel investigational human enzyme replacement candidate in Phase 3 development for the treatment of classical homocystinuria (HCU).

Learn More

About classical homocystinuria

Classical HCU is a rare metabolic disorder characterized by elevated levels of plasma homocysteine that can result in life-threatening thrombotic events such as stroke, pulmonary embolism and deep vein thrombosis, ophthalmologic and skeletal complications, as well as developmental delay.

Learn More

Investigational medicine: civorebrutinib

Civorebrutinib is an oral covalent reversible Bruton’s tyrosine kinase (BTK) inhibitor being evaluated for the treatment of primary membranous nephropathy (pMN) .

Licensing agreement

In 2026, Travere Therapeutics entered into an exclusive licensing and collaboration agreement with Everest Medicines to develop and commercialize civorebrutinib in all markets outside China and certain countries in East and Southeast Asia. The civorebrutinib-related research in the pipeline chart above refers to Everest Medicines’ studies of civorebrutinib.

Investigational medicine: civorebrutinib

Civorebrutinib is an oral covalent reversible Bruton’s tyrosine kinase (BTK) inhibitor being evaluated for the treatment of immune-mediated FSGS, IgAN, and minimal change disease (MCD).

Licensing agreement

In 2026, Travere entered into an exclusive licensing and collaboration agreement with Everest Medicines to develop and commercialize civorebrutinib in all markets outside China and certain countries in East and Southeast Asia. The civorebrutinib-related research in the pipeline chart above refers to Everest Medicines’ studies of civorebrutinib.

Investigational medicine: civorebrutinib

Civorebrutinib is an oral covalent reversible Bruton’s tyrosine kinase (BTK) inhibitor being evaluated for the treatment of immune-mediated rare kidney diseases.

Licensing agreement

In 2026, Travere Therapeutics entered into an exclusive licensing and collaboration agreement with Everest Medicines to develop and commercialize civorebrutinib in all markets outside China and certain countries in East and Southeast Asia. The civorebrutinib-related research in the pipeline chart above refers to Everest Medicines’ studies of civorebrutinib.